GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

MXCT · Dec 31, 2025

MAXCYTE, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001104659-26-034557General Corporate
Capex intensity40thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

8.44% · OPTIONAL · VALID

Operating cash generation50thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-164.19% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient
Evidence method

Yoy · gp.fundamentals.revenue

-5.66% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure0thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

36.01% · OPTIONAL · VALID

Gross margin30thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.gross_margin

127.90% · CORE · VALID

Operating margin40thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.operating_margin

-247.64% · CORE · VALID

R&D intensity10thOwn-history percentile · N=10
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

99.36% · OPTIONAL · VALID

SBC intensity10thOwn-history percentile · N=10
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

43.96% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesHistory building
Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20250/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20257/8 normalizedLevel 3Dec 31, 20257/8 normalizedLevel 3Mar 31, 20267/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition

What moved in the state?

Capex Intensity Increased
Previous
6.52%
Current
8.44%
Delta
1.92%
Cash Generation Decreased
Previous
-162.02%
Current
-164.19%
Delta
-2.17%
Growth Increased
Previous
-17.98%
Current
-5.66%
Delta
12.32%
Inventory Pressure Decreased
Previous
165.35%
Current
36.01%
Delta
-129.34%
Margin Increased
Previous
113.69%
Current
127.90%
Delta
14.21%
Profitability Increased
Previous
-307.39%
Current
-247.64%
Delta
59.75%
R And D Intensity Decreased
Previous
115.49%
Current
99.36%
Delta
-16.13%
Sbc Intensity Increased
Previous
42.45%
Current
43.96%
Delta
1.51%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · MXCT Fundamental State →Has State · MAXCYTE, INC. →Transitioned To · MXCT Fundamental State →Transitioned To · MXCT CAPEX_INTENSITY_INCREASED →Transitioned To · MXCT CASH_GENERATION_DECREASED →Transitioned To · MXCT GROWTH_INCREASED →Transitioned To · MXCT INVENTORY_PRESSURE_DECREASED →Transitioned To · MXCT MARGIN_INCREASED →Transitioned To · MXCT PROFITABILITY_INCREASED →Transitioned To · MXCT R_AND_D_INTENSITY_DECREASED →Transitioned To · MXCT SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.